G1 THERAPEUTICS INC (GTHX)
US3621LQ1099 - Common Stock
We assign a fundamental rating of 2 out of 10 to GTHX. GTHX was compared to 588 industry peers in the Biotechnology industry. GTHX may be in some trouble as it scores bad on both profitability and health. GTHX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year GTHX has reported negative net income.
GTHX had a negative operating cash flow in the past year.
GTHX had negative earnings in each of the past 5 years.
GTHX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
GTHX has a Return On Assets of -39.47%. This is in the better half of the industry: GTHX outperforms 61.30% of its industry peers.
GTHX's Return On Equity of -135.56% is on the low side compared to the rest of the industry. GTHX is outperformed by 62.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.47% | ||
| ROE | -135.56% | ||
| ROIC | N/A |
ROA(3y)-58.78%
ROA(5y)-52.55%
ROE(3y)-151.24%
ROE(5y)-111.52%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of GTHX (91.28%) is better than 93.66% of its industry peers.
GTHX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GTHX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GTHX has been increased compared to 1 year ago.
The number of shares outstanding for GTHX has been increased compared to 5 years ago.
Compared to 1 year ago, GTHX has a worse debt to assets ratio.
2.2 Solvency
GTHX has an Altman-Z score of -7.09. This is a bad value and indicates that GTHX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.09, GTHX is doing worse than 69.69% of the companies in the same industry.
GTHX has a Debt/Equity ratio of 1.46. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.46, GTHX is not doing good in the industry: 80.65% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.09 |
ROIC/WACCN/A
WACC9.66%
2.3 Liquidity
A Current Ratio of 3.87 indicates that GTHX has no problem at all paying its short term obligations.
GTHX has a Current ratio of 3.87. This is comparable to the rest of the industry: GTHX outperforms 43.84% of its industry peers.
A Quick Ratio of 3.45 indicates that GTHX has no problem at all paying its short term obligations.
GTHX has a Quick ratio of 3.45. This is comparable to the rest of the industry: GTHX outperforms 40.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.87 | ||
| Quick Ratio | 3.45 |
3. Growth
3.1 Past
GTHX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.98%, which is quite impressive.
Looking at the last year, GTHX shows a very strong growth in Revenue. The Revenue has grown by 60.84%.
The Revenue has been growing by 22.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)71.98%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q71.23%
Revenue 1Y (TTM)60.84%
Revenue growth 3Y22.13%
Revenue growth 5YN/A
Revenue growth Q2Q45.1%
3.2 Future
GTHX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.01% yearly.
GTHX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.36% yearly.
EPS Next Y26.19%
EPS Next 2Y23.17%
EPS Next 3Y25.33%
EPS Next 5Y17.01%
Revenue Next Year-13.51%
Revenue Next 2Y13.18%
Revenue Next 3Y17.62%
Revenue Next 5Y19.36%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
GTHX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GTHX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as GTHX's earnings are expected to grow with 25.33% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.17%
EPS Next 3Y25.33%
5. Dividend
5.1 Amount
GTHX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
G1 THERAPEUTICS INC
NASDAQ:GTHX (4/25/2024, 5:06:49 PM)
After market: 3.86 0 (0%)3.86
-0.13 (-3.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap201.49M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.47% | ||
| ROE | -135.56% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.28% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.87 | ||
| Quick Ratio | 3.45 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)71.98%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y26.19%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)60.84%
Revenue growth 3Y22.13%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y